CoChat
Sign Up
Cited by 95

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory.

Puzzo, Daniela, Privitera, Lucia, Palmeri, Agostino·2012·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2011.12.020
Open this paper in CoChat — free account

Abstract

One of the hot topics in Alzheimer's disease research field is the "amyloid hypothesis" postulating that the increase and deposition of beta-amyloid peptides (Aβ) is the main pathogenetic factor. However, antiamyloid-based therapies have so far been a failure and, most importantly, growing evidences suggest that Aβ has important physiologic functions. Based on our previous findings demonstrating that low concentrations of Aβ enhanced both synaptic plasticity and memory, whereas high concentrations induced the well-known impairment of cognition, here we show that Aβ acts on hippocampal long-term potentiation and reference memory drawing biphasic dose-response curves. This phenomenon, characterized by low-dose stimulation and high-dose inhibition and represented by a U-shaped or inverted-U-shaped curve, resembles the characteristics of hormesis. The Aβ double role raises important issues on the use of Aβ level reducing agents in Alzheimer's disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2011.12.020

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 64

  1. Albuquerque, 2009, Mammalian nicotinic acetylcholine receptors: from structure to function, Physiol. Rev, 89, 73, 10.1152/physrev.00015.2008 · DOI · Paper page
  2. Beach, 2001, Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists, Brain Res, 905, 220, 10.1016/S0006-8993(01)02484-2 · DOI
  3. Blennow, 2004, Cerebrospinal fluid protein biomarkers for Alzheimer's disease, Neurorx, 1, 213, 10.1602/neurorx.1.2.213 · DOI
  4. Bliss, 1993, A synaptic model of memory: long-term potentiation in the hippocampus, Nature, 361, 31, 10.1038/361031a0 · DOI · Paper page
  5. Caccamo, 2006, M1 receptors play a central role in modulating AD-like pathology in transgenic mice, Neuron, 49, 671, 10.1016/j.neuron.2006.01.020 · DOI · Paper page
  6. Calabrese, 2001, Amyloid β-Peptide: Biphasic Dose Responses, Crit. Rev. Toxicol, 31, 605, 10.1080/20014091111857 · DOI
  7. Calabrese, 2001, Nitric Oxide: Biphasic Dose Responses, Crit. Rev. Toxicol, 31, 489, 10.1080/20014091111776 · DOI
  8. Calabrese, 2008, Hormesis and medicine, Br. J. Clin. Pharmacol, 66, 594, 10.1111/j.1365-2125.2008.03243.x · DOI
  9. Calabrese, 2008, Neuroscience and hormesis: overview and general findings, Crit. Rev. Toxicol, 38, 249, 10.1080/10408440801981957 · DOI
  10. Calabrese, 2009, Getting the dose-response wrong: why hormesis became marginalized and the threshold model accepted, Arch. Toxicol, 83, 227, 10.1007/s00204-009-0411-5 · DOI
  11. Calabrese, 2010, Hormesis is central to toxicology, pharmacology and risk assessment, Hum. Exp. Toxicol, 29, 249, 10.1177/0960327109363973 · DOI
  12. Calabrese, 1998, A general classification of U-shaped dose-response relationships in toxicology and their mechanistic foundations, Hum. Exp. Toxic, 17, 353, 10.1191/096032798678908918 · DOI
  13. Calabrese, 2001, U-shaped dose–responses in biology, toxicology, and public health, Annu. Rev. Public Health, 22, 15, 10.1146/annurev.publhealth.22.1.15 · DOI
  14. Calabrese, 2002, Defining hormesis, Hum. Exp. Toxicol, 21, 91, 10.1191/0960327102ht217oa · DOI
  15. Calabrese, 2003, Hormesis: the dose-response devolution, Annu. Rev. Pharmacol. Toxicol, 43, 175, 10.1146/annurev.pharmtox.43.100901.140223 · DOI
  16. Calabrese, 2003, Peptides and Hormesis, Crit. Rev. Toxicol, 33, 355, 10.1080/713611042 · DOI
  17. Calabrese, 1999, Hormesis: a highly generalizable and reproducible phenomenon with important implications for risk assessment, Risk Anal, 19, 261, 10.1111/j.1539-6924.1999.tb00404.x · DOI
  18. Choi, 1988, Glutamate neurotoxicity and diseases of the nervous system, Neuron, 1, 623, 10.1016/0896-6273(88)90162-6 · DOI
  19. Chow, 2010, An Overview of APP Processing Enzymes and Products, Neuromol. Med, 12, 1, 10.1007/s12017-009-8104-z · DOI · Paper page
  20. Cirrito, 2008, Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo, Neuron, 58, 42, 10.1016/j.neuron.2008.02.003 · DOI · Paper page
  21. Clader, 2005, Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease, Curr. Pharm. Des, 11, 3353, 10.2174/138161205774370762 · DOI
  22. Cummings, 2010, What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?, Biol. Psych, 68, 876, 10.1016/j.biopsych.2010.09.020 · DOI
  23. Dawson, 1999, Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein, Neuroscience, 90, 1, 10.1016/S0306-4522(98)00410-2 · DOI
  24. Dineley, 2002, Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes, J. Biol. Chem, 277, 25056, 10.1074/jbc.M200066200 · DOI
  25. Dineley, 2001, Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease, J. Neurosci, 21, 4125, 10.1523/JNEUROSCI.21-12-04125.2001 · DOI · Paper page
  26. Dominguez, 2002, Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease, Trends Pharmacol. Sci, 23, 324, 10.1016/S0165-6147(02)02038-2 · DOI
  27. Duncan, 2005, Nitric oxide and neurological disorders, Mol. Aspects Med, 26, 67, 10.1016/j.mam.2004.09.004 · DOI
  28. Fehér, 2009, Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia, Dement. Geriatr. Cogn. Disord, 28, 56, 10.1159/000230036 · DOI
  29. Fodero, 2004, Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones, J. Neurochem, 88, 1186, 10.1046/j.1471-4159.2003.02296.x · DOI
  30. Giuffrida, 2010, The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology, Rev. Neurosci, 21, 83, 10.1515/REVNEURO.2010.21.2.83 · DOI
  31. Grassi, 2003, Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors, J. Physiol, 547, 147, 10.1113/jphysiol.2002.035436 · DOI
  32. Gray, 1996, Hippocampal synaptic transmission enhanced by low concentrations of nicotine, Nature, 383, 713, 10.1038/383713a0 · DOI
  33. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  34. Kamenetz, 2003, APP processing and synaptic function, Neuron, 37, 925, 10.1016/S0896-6273(03)00124-7 · DOI · Paper page
  35. Kastin, 2008, Peptides and Hormesis, Crit. Rev. Toxicol, 38, 629, 10.1080/10408440802026372 · DOI
  36. Kendig, 2010, Defining hormesis: evaluation of a complex concentration response phenomenon, Int. J. Toxicol, 29, 235, 10.1177/1091581810363012 · DOI
  37. Laird, 2005, BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions, J. Neurosci, 25, 11693, 10.1523/JNEUROSCI.2766-05.2005 · DOI · Paper page
  38. Levey, 1996, Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A, 93, 13541, 10.1073/pnas.93.24.13541 · DOI
  39. Levin, 2002, Nicotinic receptor subtypes and cognitive function, J. Neurobiol, 53, 633, 10.1002/neu.10151 · DOI · Paper page
  40. Lewczuk, 2006, Effect of sample col- lection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides, Clin. Chem, 52, 332, 10.1373/clinchem.2005.058776 · DOI
  41. López-Toledano, 2004, Neurogenic effect of β-amyloid peptide in the development of neural stem cells, J. Neurosci, 24, 5439, 10.1523/JNEUROSCI.0974-04.2004 · DOI · Paper page
  42. Lowenstein, 1994, Nitric oxide: a physiologic messenger, Ann. Intern. Med, 120, 227, 10.7326/0003-4819-120-3-199402010-00009 · DOI
  43. Lupien, 2005, Hormetic Influence of Glucocorticoids on Human Memory, Nonlinearity Biol. Toxicol. Med, 3, 23, 10.2201/nonlin.003.01.003 · DOI
  44. Ma, 2007, Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity, Proc. Natl. Acad. Sci. U. S. A, 104, 8167, 10.1073/pnas.0609521104 · DOI
  45. Mattson, 2004, Pathways towards and away from Alzheimer's disease, Nature, 430, 631, 10.1038/nature02621 · DOI · Paper page
  46. Mattson, 2008, Glutamate and neurotrophic factors in neuronal plasticity and disease, Ann. N. Y. Acad. Sci, 1144, 97, 10.1196/annals.1418.005 · DOI · Paper page
  47. Mattson, 2008, Hormesis and disease resistance: activation of cellular stress response pathways, Hum. Exp. Toxicol, 27, 155, 10.1177/0960327107083417 · DOI · Paper page
  48. Medeiros, 2011, Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline, Am. J. Pathol, 179, 980, 10.1016/j.ajpath.2011.04.041 · DOI
  49. Oddo, 2006, The role of nicotinic acetylcholine receptors in Alzheimer's disease, J. Physiol. Paris, 99, 172, 10.1016/j.jphysparis.2005.12.080 · DOI
  50. Phinney, 1999, No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice, Neuroscience, 90, 1207, 10.1016/S0306-4522(98)00645-9 · DOI
  51. Plant, 2003, The production of amyloid beta peptide is a critical requirement for the viability of central neurons, J. Neurosci, 23, 5531, 10.1523/JNEUROSCI.23-13-05531.2003 · DOI
  52. Puzzo, 2006, Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease, Rev. Neurosci, 17, 497, 10.1515/REVNEURO.2006.17.5.497 · DOI
  53. Puzzo, 2011, Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory, Ann. Neurol, 69, 819, 10.1002/ana.22313 · DOI · Paper page
  54. Radcliffe, 1998, Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission, J. Neurosci, 18, 7075, 10.1523/JNEUROSCI.18-18-07075.1998 · DOI · Paper page
  55. Randall, 2010, The functional neurophysiology of the amyloid precursor protein (APP) processing pathway, Neuropharmacology, 59, 243, 10.1016/j.neuropharm.2010.02.011 · DOI
  56. Schenk, 1985, Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions, Exp. Brain Res, 58, 11, 10.1007/BF00238949 · DOI · Paper page
  57. Seabrook, 1999, Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein, Neuropharmacology, 38, 349, 10.1016/S0028-3908(98)00204-4 · DOI
  58. Seo, 2002, Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice, Eur. J. Neurosci, 15, 498, 10.1046/j.0953-816x.2001.01884.x · DOI
  59. Small, 2007, The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor, J. Neurochem, 101, 1527, 10.1111/j.1471-4159.2006.04444.x · DOI · Paper page
  60. Trinchese, 2004, Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice, Ann. Neurol, 55, 801, 10.1002/ana.20101 · DOI
  61. Wang, 2008, BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus, J. Neurosci, 28, 8677, 10.1523/JNEUROSCI.2440-08.2008 · DOI
  62. Wang, 2000, Beta-amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity, J. Biol. Chem, 275, 5626, 10.1074/jbc.275.8.5626 · DOI
  63. Wieloch, 1985, Hypoglycemia-induced neuronal damage prevented by an N-methyl-d-aspartate antagonist, Science, 230, 681, 10.1126/science.2996146 · DOI
  64. Williams, 2011, Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study, Alz. Res. Ther, 3, 5, 10.1186/alzrt64 · DOI

Cited by

Sorted by citations

Metadata

Authors
Puzzo, D., Privitera, L., & Palmeri, A.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2012-07
Volume
33
Issue
7
Pages
1484.e15-1484.e24
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2011.12.020
Cited by
95
References
7
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Alzheimer's Association (IIRG-09-134220)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review